DrugBiological
Oprelvekin clinical trials
Also written rhIL-11.
A product of Interleukin-11; its studies count on that page too.
- studies test it
- 11
- open now
- 0
- in phase 3
- 1
- first study started
- 2000
How studies write it
Studies that test it under each name
Name
Brand
Development codes
Studies by the year they started
10 studies that test it; most in 2008 (2)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2002 | 1 |
| 2004 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 8
- Phase 3
- 1
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 8
Margaret Ragni (2) · University of Pittsburgh (2) · Wyeth is now a wholly owned subsidiary of Pfizer (2) · Shanghai Children's Medical Center (1) · Fred Hutchinson Cancer Center (1) · National Cancer Institute (NCI) (1) · Pfizer (1) · Zhejiang Cancer Hospital (1)
Often tested with
Tested in the same studies.
Filgrastim (2) · Rituximab (1) · Yttrium Y-90 ibritumomab tiuxetan (1) · Ibritumomab tiuxetan (1)
Studies
Open first, then newest update. How each study uses oprelvekin is read from its arms, and is right about nine times in ten.
Testing it · 11
- Interleukin-11 Can Prevent and Treat of Radioactive Oral MucitisStatus unknownPhase 3Zhejiang Cancer HospitalNCT03720340Written as Recombinant Human Interleukin-11
- IL-11 in Adults With Von Willebrand Disease Undergoing SurgeryTerminatedPhase 2Margaret RagniNCT00524225Written as Neumega (Oprelvekin, Interleukin 11, IL-11)
- Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaTerminatedPhase 1/2National Cancer Institute (NCI)NCT00012298Written as oprelvekin
- IL-11 in Women With Von Willebrand Disease and Refractory MenorrhagiaCompletedPhase 2Margaret RagniNCT00524342Written as Oprelvekin, Interleukin 11, IL-11
- Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced ThrombocytopeniaTerminatedPhase 2PfizerNCT00886743Written as oprelvekin
- Phase II Study of IL-11 (Neumega) in Von Willebrand DiseaseCompletedPhase 2University of PittsburghNCT00151125Written as recombinant interleukin-11
- Efficacy and Safety of IL-11 in DDAVP UnresponsiveCompletedPhase 2University of PittsburghNCT00994929Written as Neumega (Oprelvekin, Interleukin 11, IL-11)
- Effect of rhIL-11 in Patients With Thrombocytopenia for Childhood ALLCompletedPhase 4Shanghai Children's Medical CenterNCT02314273Written as rhIL-11
- Study Evaluating rhIL-11 in Active Crohn's DiseaseCompletedPhase 2Wyeth is now a wholly owned subsidiary of PfizerNCT00040521Written as Recombinant Human Interleukin-11 (rhIL-11)
- Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid TumorsCompletedPhase 2Fred Hutchinson Cancer CenterNCT00004157Written as recombinant interleukin-11
- Study Evaluating rhIL-11 in Left-Sided Ulcerative ColitisTerminatedPhase 1Wyeth is now a wholly owned subsidiary of PfizerNCT00038922Written as rhIL-11
As the comparator · 3 — what is tested is compared with oprelvekin
- A Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11RecruitingPhase 3The First Affiliated Hospital with Nanjing Medical UniversityNCT06759636Written as Recombinant Human Interleukin-11 (rhIL-11)
- A Phase Ⅲa Study of Genetically Modified Recombinant Human Interleukin-11CompletedPhase 3Beijing Northland Biotech. Co., Ltd.NCT01663441Written as rhIL-11
- Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With ThrombocytopeniaStatus unknownPhase 2Fudan UniversityNCT03823079Written as rhIL-11
Codes
What other systems call oprelvekin · ClinicalTrials.gg INT003977
- MeSH (NLM) C105308oprelvekinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) HM5641GA6FOPRELVEKINConfirmed FDA, NLM, Wikidata
- RxNorm 139994Confirmed FDA, Wikidata
- Wikidata Q7098691oprelvekinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1303OprelvekinOne source FDA
- DrugBank DB00038One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C105308 | oprelvekin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | HM5641GA6F | OPRELVEKIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 139994 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7098691 | oprelvekin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1303 | Oprelvekin | One source FDA |
| DrugBank | DB00038 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.